Literature DB >> 12583996

Construction of a novel set of transfer vectors to study vaccinia virus replication and foreign gene expression.

Barbara Dvoracek1, Teri Shors.   

Abstract

Vaccinia virus (VV) is a useful expression vector for many laboratory applications. To date, approximately 60% ( approximately 120) of the VV genes remain uncharacterized. The thought of smallpox being used as a biological weapon has gained attention. In light of this, it is imperative that we continue to study the basic replication of VV, a poxvirus that is closely related to smallpox. A set of plasmid vectors were constructed to generate gene deletions (pZIPPY-NEO/GUS) in VV or for foreign gene expression (pBR-EXPRESS). The vectors contain the Escherichia coli neomycin resistance (neo) and beta-glucuronidase (gusA) genes as selectable markers to facilitate isolation of recombinant viruses. These are the first transfer vectors to use a neo/gusA selection system. We used these vectors to successfully generate a recombinant D9R deletion mutant of VV and to express E. coli lacZ gene. Results indicate that both vectors are highly suited for their designed purpose. Copyright 2002 Elsevier Science (USA)

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12583996     DOI: 10.1016/s0147-619x(02)00154-3

Source DB:  PubMed          Journal:  Plasmid        ISSN: 0147-619X            Impact factor:   3.466


  11 in total

1.  Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression.

Authors:  Susan Parrish; Bernard Moss
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-kappaB activation during infection.

Authors:  Olivia Hinthong; Xiao-Lu Jin; Joanna L Shisler
Journal:  Virology       Date:  2008-01-10       Impact factor: 3.616

3.  Vaccinia virus nicking-joining enzyme is encoded by K4L (VACWR035).

Authors:  Dawn Eckert; Ollie Williams; Clement A Meseda; Michael Merchlinsky
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  A novel inhibitor of the NF-{kappa}B signaling pathway encoded by the parapoxvirus orf virus.

Authors:  D G Diel; G Delhon; S Luo; E F Flores; D L Rock
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

5.  Orf virus ORFV121 encodes a novel inhibitor of NF-kappaB that contributes to virus virulence.

Authors:  D G Diel; S Luo; G Delhon; Y Peng; E F Flores; D L Rock
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

6.  A nuclear inhibitor of NF-kappaB encoded by a poxvirus.

Authors:  D G Diel; S Luo; G Delhon; Y Peng; E F Flores; D L Rock
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

7.  Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.

Authors:  Don B Gammon; Branawan Gowrishankar; Sophie Duraffour; Graciela Andrei; Chris Upton; David H Evans
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

8.  Vaccinia virus mutants with alanine substitutions in the conserved G5R gene fail to initiate morphogenesis at the nonpermissive temperature.

Authors:  Flavio G da Fonseca; Andrea S Weisberg; Maria F Caeiro; Bernard Moss
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Generation of recombinant Orf virus using an enhanced green fluorescent protein reporter gene as a selectable marker.

Authors:  Zhangyong Ning; Yongzheng Peng; Wenbo Hao; Chaohui Duan; Daniel L Rock; Shuhong Luo
Journal:  BMC Vet Res       Date:  2011-12-22       Impact factor: 2.741

10.  A single vertebrate DNA virus protein disarms invertebrate immunity to RNA virus infection.

Authors:  Don B Gammon; Sophie Duraffour; Daniel K Rozelle; Heidi Hehnly; Rita Sharma; Michael E Sparks; Cara C West; Ying Chen; James J Moresco; Graciela Andrei; John H Connor; Darryl Conte; Dawn E Gundersen-Rindal; William L Marshall; John R Yates; Neal Silverman; Craig C Mello
Journal:  Elife       Date:  2014-06-25       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.